AbbVie Inc. ABBV SPXR3KPHARMA
Company Overview
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Why Investors Should Care
Operating margin of 40.0% supports profitability.
Offers a dividend yield of 2.54%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $61.16B (+8.6% YoY); net profit $4.23B.
- Trailing 12 Months Year-on-year growth — revenue +10.2%, earnings +290.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.8%, profit CAGR -29.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.75% |
| 1 Year: | 10.20% |
Compounded Profit Growth
| 5 Years: | -29.06% |
| 1 Year: | 290.40% |
Stock Price Performance
| 1 Year: | +46.18% |
| 6 Months: | +45.66% |
| 3 Months: | +11.87% |
| 1 Month: | +8.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.13 · Neutral
P/E of 80.69 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 2.54%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 80.7.
- Earnings shrank at -29.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 7 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 439.26 | 27.28 | $237.48B | 2.44% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 6.54B | 6.94B | 7.00B | - | 7.93B | 8.28B | 8.24B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.34B | 15.42B | 15.78B | 16.62B | 15.00B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00B | 4.35B | 5.30B | 4.55B | 4.22B | - |
| Gross Profit | 4.93B | 5.24B | 4.92B | 5.42B | 5.38B | 5.46B | 6.01B | 6.34B | 6.40B | 6.28B | 6.13B | 6.44B | 6.56B | 6.70B | - | - | - | 9.17B | - | - | - | 10.57B | - | - | - | 10.95B | - | - | - | 8.60B | - | - | - | - | 9.34B | 11.08B | 10.47B | 12.07B | 10.78B | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.36B | 5.36B | 5.89B | 6.26B | 6.05B | - |
| Operating Income | 2.36B | - | 2.41B | 2.66B | 2.69B | - | 2.90B | 2.76B | 3.16B | - | 3.01B | 3.40B | 2.62B | - | 3.60B | 752.00M | 3.25B | - | 4.10B | 4.44B | 4.31B | - | 4.72B | 3.29B | 4.60B | - | 2.77B | 4.51B | 2.28B | - | 2.80B | 4.00B | 3.83B | - | 3.98B | 5.72B | 4.58B | 5.81B | 4.73B | 6.43B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.40B | 4.34B | 3.52B | 5.37B | 3.69B | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 700.00M | 740.00M | 739.00M | 714.00M | 717.00M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.66B | 1.55B | 714.00M | 2.67B | 1.04B | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 372.00M | 613.00M | 526.00M | 853.00M | 342.00M | - |
| Net Income | 1.60B | 1.39B | 1.71B | 1.92B | 1.63B | 52.00M | 2.78B | 1.98B | 2.75B | -1.83B | 2.46B | 741.00M | 1.88B | 2.80B | 3.01B | -738.00M | 2.31B | 36.00M | 3.55B | 766.00M | 3.18B | 4.04B | 4.49B | 924.00M | 3.95B | 2.47B | 239.00M | 2.02B | 1.78B | 822.00M | 1.37B | 1.37B | 1.56B | - | 1.29B | 938.00M | 186.00M | 1.82B | 695.00M | 3.61B |
| Diluted EPS | 0.97 | 0.85 | 1.06 | 1.19 | 1.01 | 0.03 | 1.74 | 1.26 | 1.81 | -1.23 | 1.65 | 0.49 | 1.26 | 1.88 | 2.02 | -0.46 | 1.29 | 0.01 | 1.99 | 0.42 | 1.78 | 2.26 | 2.51 | 0.51 | 2.21 | 1.38 | 0.13 | 1.14 | 1.00 | 0.46 | 0.77 | 0.77 | 0.88 | - | 0.72 | 0.52 | 0.10 | 1.02 | 0.39 | 2.03 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.44B | 18.38B | 18.79B | 19.96B | 22.86B | 25.64B | 28.22B | 32.75B | 33.27B | 45.80B | 56.20B | 58.05B | 54.32B | 56.33B | 61.16B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 17.41B | 20.41B | 16.90B | 18.20B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 40.64B | 33.90B | 39.43B | 42.96B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 21.83B | 20.37B | 27.54B | 22.86B |
| Operating Income | 3.62B | 5.82B | 5.66B | 3.41B | 7.54B | 9.34B | 9.54B | 6.38B | 12.98B | 11.36B | 17.92B | 18.81B | 13.54B | 11.89B | 20.09B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | 24.17B | 17.17B | 14.91B | 17.63B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 2.23B | 2.22B | 2.81B | 2.89B |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | 13.48B | 6.25B | 3.72B | 6.60B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 1.63B | 1.38B | -570.00M | 2.36B |
| Net Income | 3.43B | 5.28B | 4.13B | 1.77B | 5.14B | 5.95B | 5.31B | 5.69B | 7.88B | 4.62B | 11.54B | 11.84B | 4.86B | 4.28B | 4.23B |
| Diluted EPS | 2.18 | 3.35 | 2.56 | 1.10 | 3.13 | 3.63 | 3.30 | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 27.01B | 29.20B | 27.51B | 53.05B | 66.10B | 70.79B | 59.35B | 89.11B | 150.56B | - | 138.81B | 134.71B | 135.16B | 133.96B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 28.46B | 33.00B | 25.58B | 29.06B |
| Cash & Equivalents | 10.00M | 27.00M | 5.90B | 9.60B | 8.35B | 8.40B | 5.10B | 9.30B | 7.29B | 39.92B | 8.45B | - | 9.20B | 12.81B | 5.52B | 5.23B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 3.58B | 4.10B | 4.18B | 4.95B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 11.25B | 11.15B | 10.92B | 12.59B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 121.52B | 124.31B | 131.80B | 137.19B |
| Current Liabilities | - | - | 6.78B | 6.88B | 11.39B | 10.89B | 9.78B | 16.64B | 17.24B | 15.59B | 28.66B | - | 29.54B | 37.84B | 38.75B | 43.29B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 67.23B | 84.95B | - | 59.13B | 52.19B | 60.34B | 58.94B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 63.27B | 59.38B | 67.14B | 67.50B |
| Total Equity | - | - | -350.00M | 4.49B | 1.74B | 3.94B | 4.64B | 5.10B | -8.45B | -8.17B | 13.08B | - | 17.25B | 10.36B | 3.33B | -3.27B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 1.81B | 1.82B | 1.83B | 1.84B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | 9.96B | 13.43B | 13.32B | 17.59B | - | 24.94B | 22.84B | 18.81B | 19.03B |
| Investing Cash Flow | - | - | - | - | - | - | -274.00M | -1.01B | 596.00M | -37.56B | - | -623.00M | -2.01B | -20.82B | -6.64B |
| Financing Cash Flow | - | - | - | - | - | -3.93B | -5.51B | -14.40B | 18.71B | -11.50B | - | -24.80B | -17.22B | -5.21B | -12.72B |
| Capital Expenditure | -356.00M | -333.00M | -491.00M | -612.00M | -532.00M | -479.00M | -529.00M | -638.00M | -552.00M | -798.00M | - | -695.00M | -777.00M | -974.00M | -1.21B |
| Free Cash Flow | - | - | - | - | - | - | 9.43B | 12.79B | 12.77B | 16.79B | - | 24.25B | 22.06B | 17.83B | 17.82B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -483.00M | 3.61B | -7.22B | -337.00M |
| Share Buybacks | - | - | 320.00M | 665.00M | 7.59B | 6.03B | 1.41B | 12.01B | 629.00M | 978.00M | 934.00M | 1.49B | 1.97B | 1.71B | 980.00M |
| Dividends Paid | - | - | 2.56B | 2.66B | 3.29B | 3.72B | 4.11B | 5.58B | 6.37B | 7.72B | 9.26B | 10.04B | 10.54B | 11.03B | 11.66B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 70.0% | 62.4% | 70.0% | 70.2% |
| Operating Margin % | 20.8% | 31.6% | 30.1% | 17.1% | 33.0% | 36.4% | 33.8% | 19.5% | 39.0% | 24.8% | 31.9% | 32.4% | 24.9% | 21.1% | 32.8% |
| Net Margin % | 19.7% | 28.7% | 22.0% | 8.9% | 22.5% | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| ROE % | - | -1,507.1% | 91.9% | 101.8% | 130.4% | 128.4% | 104.2% | -67.3% | -96.5% | 35.3% | - | 68.6% | 46.9% | 128.7% | -129.2% |
| ROCE % | - | 28.8% | 25.4% | 21.2% | 17.9% | 16.6% | 17.6% | 15.2% | 17.7% | 9.3% | - | 17.2% | 14.0% | 12.3% | 22.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.46% | 149.49M | $41.33B |
| 2 | Vanguard Capital Management LLC | 6.53% | 115.40M | $31.90B |
| 3 | State Street Corporation | 4.67% | 82.60M | $22.84B |
| 4 | Vanguard Portfolio Management LLC | 2.74% | 48.48M | $13.40B |
| 5 | JPMORGAN CHASE & CO | 2.71% | 47.86M | $13.23B |
| 6 | Geode Capital Management, LLC | 2.66% | 47.00M | $12.99B |
| 7 | Morgan Stanley | 2.20% | 38.90M | $10.75B |
| 8 | Capital Research Global Investors | 1.70% | 30.10M | $8.32B |
| 9 | NORGES BANK | 1.45% | 25.55M | $7.07B |
| 10 | Bank of America Corporation | 1.20% | 21.24M | $5.87B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ABBV
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now…
AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?
When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge varies far more than the yields suggest.…
Global Dental Soft Tissue Wound Care Market Size, Share, and Forecast by Product, 2026-2032 | Plug, Tape, and Foam Demand to Drive 11.8% CAGR and a $390 Million Market
The global dental soft tissue wound care market is projected to grow from nearly $180 million in 2025 to nearly $390 million by 2032, a new Research and Markets report finds, with ZimVie leading ahead of AbbVie and Henry Schein, though cost…
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie’s skin disease drug posts Phase III win as market competition heats up
This late-stage readout comes as companies explore the potential of novel mechanisms of action in HS.
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
They definitely matter... up to a point.
ABBV — Frequently Asked Questions
What is the current share price of AbbVie Inc. (ABBV)?
As of 2026-10-23 16:27 PDT, AbbVie Inc. (ABBV) trades at $285.64 on NYSE. Its 52-week range is $194.79 to $289.08.
What is the market capitalisation of ABBV?
AbbVie Inc. (ABBV) has a market capitalisation of $504.76B on NYSE.
What is the P/E ratio of ABBV?
ABBV trades at a trailing price-to-earnings (P/E) ratio of 80.69. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -82.31.
Does ABBV pay a dividend?
AbbVie Inc. (ABBV) currently offers a dividend yield of 2.54%.
What is the return on equity (ROE) of ABBV?
ABBV has a return on equity (ROE) of -129.24%. Its return on capital employed (ROCE) is 10.47%.
Is ABBV a good stock to buy?
This page provides a data-driven analysis of AbbVie Inc. (ABBV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.